Eton Pharmaceuticals Inc. reported its financial results for the first quarter of 2025, highlighting significant growth in product sales and revenues. The company achieved Q1 2025 revenue of $17.3 million, with product sales accounting for $14.0 million. This represents a 76% increase over the same period in 2024 and marks the 17th consecutive quarter of sequential product sales growth. The growth was primarily driven by the momentum of ALKINDI SPRINKLE® and the recent acquisition of INCRELEX®, which was relaunched in the U.S. in late December. Eton also reported an adjusted EBITDA of $3.7 million for the quarter. The company's cash position as of March 31, 2025, was $17.4 million, with $2.1 million generated in operating cash flow during the quarter. A pivotal clinical study for product candidate ET-600 yielded positive results, and the company submitted a New Drug Application to the U.S. FDA. Additionally, Eton established a Wilson disease franchise with the acquisition and relaunch of GALZIN® capsules and introduced product candidate ET-700. Eton Pharmaceuticals continues to focus on developing treatments for rare diseases, with management expressing confidence in ongoing growth throughout 2025 and beyond.